New PET tracer identifies DVT in legs and lungs

by Society of Nuclear Medicine and Molecular Imaging

edited by Lisa Lock, reviewed by Andrew Zinin

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add as preferred source

A novel PET radiotracer can accurately detect deep vein thrombosis in the legs and reveal whether clots have migrated to the lungs. By enabling whole-body imaging of blood clots in a single scan, the approach may support faster and more efficient diagnosis—particularly for patients who also require evaluation for potentially life-threatening pulmonary embolism. This research was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, and the collection of images showcasing the visualization of blood clots in the legs and in the lungs has been selected as the 2026 SNMMI Henry N. Wagner, Jr., Image of the Year.

Each year, SNMMI chooses an image that best exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence, and providing a means of selecting appropriate treatments. This year, the SNMMI Image of the Year was chosen from nearly 1,500 abstracts submitted for the meeting.

Deep vein thrombosis is a common disease in which blood clots form in the legs and, in some cases, travel to the lungs as a pulmonary embolism. It affects approximately 900,000 Americans a year, according to the Centers for Disease Control and Prevention. Early detection is critical to ensure prompt treatment.

"Conventional imaging techniques, such as venous ultrasound and CT, rely on indirect structural changes—like vein compressibility or contrast filling defects—rather than directly visualizing the clot itself," said Sangwon Han, MD, Ph.D., clinical assistant professor in the Department of Nuclear Medicine at Asan Medical Center, University of Ulsan College of Medicine in Seoul, Korea. "¹⁸F-GP1 PET/CT is a thrombus-specific imaging that selectively targets activated platelets, allowing blood clots to be visualized directly even in areas that may be difficult to assess with conventional imaging."

In the study, researchers assessed the diagnostic accuracy and tolerability of a novel radiotracer, ¹⁸F-GP1 PET/CT, for identifying acute lower extremity deep vein thrombosis. Forty-six symptomatic patients underwent ¹⁸F-GP1 PET/CT imaging, with scans independently evaluated by three blinded nuclear medicine physicians. Diagnostic performance for identifying clots in the thighs was compared with venous ultrasound; accuracy for detecting calf clots and detection rate for lung clots was also evaluated. Radiotracer safety was assessed throughout the study.

¹⁸F-GP1 PET/CT showed high diagnostic accuracy for detecting clots not only in the thigh but also in the calf. It also demonstrated a high detection rate of pulmonary embolism occurring together with deep vein thrombosis. ¹⁸F-GP1 PET/CT was well tolerated, with no drug-related adverse events.

"These findings suggest that a single whole-body PET scan could accurately evaluate clots in both the legs and lungs at the same time, potentially reducing the need for multiple tests while improving patient convenience," said Han.

Giuseppe Esposito, MD, SNMMI Scientific Program Committee chair, sees the potential for this radiotracer to transform the detection of acute thrombus beyond deep vein thrombosis. "This approach could serve as a platform technology for detecting clots throughout the body and even help to detect stroke or cardiovascular disease," he said. "These images show just how powerful molecular imaging can be."

¹⁸F-GP1 PET/CT has already been evaluated in Phase 2 studies for deep vein thrombosis, as well as in conditions such as embolic stroke and cardiovascular disease. With further validation through larger, multicenter Phase 3 trials, this radiotracer could become part of routine clinical practice within the next five to 10 years.

More information

Abstract 261247: Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study

Key medical concepts

Deep Vein ThrombosisPulmonary Embolism

Clinical categories

Diagnostic radiologyPulmonary medicine Provided by Society of Nuclear Medicine and Molecular Imaging Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New PET tracer identifies DVT in legs and lungs (2026, June 6) retrieved 6 June 2026 from https://medicalxpress.com/news/2026-06-pet-tracer-dvt-legs-lungs.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.